Precise correction of G6PD Viangchan mutation in iPSCs by prime editing strategy
3
Issued Date
2025-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-105013581981
Journal Title
Scientific Reports
Volume
15
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.15 No.1 (2025)
Suggested Citation
Netsawang C., Tongbaen M., Jearawiriyapaisarn N., Leecharoenkiat K. Precise correction of G6PD Viangchan mutation in iPSCs by prime editing strategy. Scientific Reports Vol.15 No.1 (2025). doi:10.1038/s41598-025-15463-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/111814
Title
Precise correction of G6PD Viangchan mutation in iPSCs by prime editing strategy
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency hold a significant risk of severe hemolytic crises under oxidative stress. Currently, the definitive and curative treatment for the disorder has not been developed. Among over 200 G6PD variants, G6PD Viangchan (c.871 G > A) is the most prevalent and has been extensively studied in Southeast Asia. This study assessed the effectiveness of prime editing for correcting the G6PD Viangchan mutation in an established mutant HEK293T cell line and G6PD-deficient induced pluripotent stem cells (iPSCs). Using optimized modalities, prime editing achieved a high correction efficiency of over 25% in the HEK293T cells. In iPSCs, this gene editing tool yielded satisfactory correction outcomes, with approximately 5% corrected alleles. Our findings indicate that prime editing provides high precision, producing minimal by-products below baseline and showing undetectable off-target effects. Overall, prime editing has the potential to correct the G6PD Viangchan mutation, providing a valuable approach for future therapeutic strategies and the generation of isogenic cell lines to promote extensive studies in drug discovery and the pathogenesis of the G6PD variant.